More great news about SCUBE3... this could be it! 2/14/2023
SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity I am a dermatologist with a clinical interest in alopecia. AMA
In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.
community This is the best time in human history to be fighting hair loss
This conversation discusses the advancements in treatments for hair loss, including finasteride, dutasteride, minoxidil and new promising treatments such as pyrilutamide and verteporfin. Other treatments discussed were taking minoxidil orally, tretinoin to turn non-responders into responders and microneedling to further boost growth.
community cosmeRNA finally now it's pyrilutamide turn
Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.
community Anyone else crying themselves to sleep because of the pyrilutamide fail?
The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.
community Is Pyrilutamide the real deal and if so when will it actually be available?
Pyrilutamide, a potential hair loss treatment that is currently in development and may be available soon; an androgen receptor degrader which is also being developed as a potential treatment for hair loss; and the comparison between Pyrilutamide, finasteride, minoxidil, and RU58841.
community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
Related Research
6 / 6 results
research Ageratum houstonianum Extract and Agerarin Promote Hair Growth via MAPK/AP-1 Axis-Dependent Upregulation of SCUBE3 in Human Dermal Papilla Cells
In this study, Ageratum houstonianum ethanolic extract and its active component agerarin were found to promote hair growth and follicle elongation by increasing SCUBE3 expression via activation of MAPK–AP-1 signaling in human dermal papilla cells, suggesting potential therapeutic value for treating hair loss.
research Rhamnose-mediated modulation of hair follicle growth: insights from chemical genomics
This study found that rhamnose can restore hair-inducing gene expression in dermal papilla cells and accelerate hair follicle regeneration by promoting the hair cycle into the anagen phase, suggesting its potential therapeutic application for alopecia treatment.
research Stem Cell Applications in Human Hair Growth: A Literature Review
This review explores stem cell applications for hair regrowth in alopecia, with no new clinical results, suggesting potential advantages over current FDA-approved treatments.
research Ginsenoside CK inhibits androgenetic alopecia by regulating Wnt/β‐catenin and p53 signaling pathways in AGA mice
In this animal study, researchers observed that ginsenoside CK significantly reduced hair loss, improved sexual organ health, and encouraged hair growth in mice with androgenetic alopecia by modulating key signaling pathways and normalizing hormone metabolism, highlighting its potential as a therapeutic agent.
research Expression of the Scube3 epidermal growth factor-related gene during early embryonic development in the mouse
This study reports that the mouse Scube3 gene is expressed in various tissues during embryonic development, including the neural tube, limb buds, developing tooth, hair follicle, and skeletal regions.
research Characterization of a mouse Scube3 reporter line
Mouse Scube3 affects teeth, tongue, vibrissae, and eye development, but not facial structure or limb growth.